A Case-Based Approach to CLL and Mantle Cell Lymphoma: Novel Therapies and Transplant Options
Using a case-based format and the latest research, experts will address the clinical management of patients with CLL and MCL and discuss both frontline and salvage therapies. Such therapies will include conventional chemotherapy as well as transplant approaches. For CLL, what is the risk-adapted sequence for treatment and who can benefit from earlier and more aggressive therapeutic interventions, including hematopoietic cell transplantation (HCT)? For MCL, what are the optimal therapeutic approaches for this challenging disease using standard agents, novel approaches, and HCT?
ACCME Accreditation Statement:
The Medical College of Wisconsin designates this activity for up to 3.5 hours of participation for continuing education for allied health professionals.
Hematologists/oncologists who treat MCL and CLL
At the conclusion of this activity, I will be able to
1. Identify biologic and clinical factors and current recommendations in selecting risk-adapted treatment for CLL.
2. Determine timing of transplant for CLL based on patient risk, disease and molecular factors.
3. Evaluate outcomes for current therapeutic approaches to MCL.
4. Compare the risks and benefits of MCL treatment approach, and how timing of transplant and clinical patient characteristics affects outcomes.
Peter Dreger, MD
Ajay Gopal, MD
Thomas Kipps, MD
Willis Navarro, MD
Julie Vose, MD
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.